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Abstract
Background and Aim: Silicone oil or gel has well-deﬁ  ned chemotactic properties on monocytes and lymphocytes 
in vivo. It results in ﬁ  brotic reaction when spread into the human tissues either incidentally or purposely and can 
slowly release any physically-enclosed lyophilized compounds due to its viscosity. Our aim is to investigate whether 
polydimethylsiloxane could be considered as an effective medium in the local treatment of cancer. 
Materials and Methods: Our study was conducted between January 2004 and December 2006 on 15 
patients with various types of cancer. The criteria for selection included patients with locally-advanced 
tumor that was rapidly growing and life threatening and those who had poor quality of life and general 
wellbeing. The patients were already discharged from the cancer centre before joining the study, after 
they had already received their chemoradiation protocol. Once a week for one month, different areas of 
the tumor were injected with 0.25 ml of polydimethylsiloxane medical grade (viscosity: 350 centistokes at 
30°C), mixed with 300,000 units of lyophilized human IL-2. Tumor biopsies were taken before the study 
was started and one week after the last injection for the histopathological analysis of the percentage of 
severe inﬂ  ammatory reaction using an image analysis system. CT scans of the tumor were taken before 
the injection cycle was started and one week after the last injection in order to determine the percentage 
change in the size of the tumor. The quality of life and general wellbeing of the patients was assessed at the 
beginning of the stud, and one week after the study was over by using the Karnofsky performance test. 
Results: Our treatment was well tolerated by the patients. They had a signiﬁ  cant improvement in their 
quality of life and general well being (p = 0.0005). The prognosis of the patients before the beginning of the 
study ranged between 1 and 6 months, while their overall survival after treatment was between 2 and 12 
months, with three patients still remaining alive. A signiﬁ  cant decrease in the tumor size was observed at 
the end of the study in 12 patients (p < 0.0001). Such a decrease was associated with a signiﬁ  cant increase 
in the percentage of the tumor containing a severe immune reaction (p < 0.0001). A signiﬁ  cant correlation 
was found between the percentage reduction in tumor size and the percentage of tumor immune reaction 
(r2 = 0.968; p < 0.0001). 
Conclusion: Polydimethylsiloxane could be used as an effective cytokine medium in the local treatment 
of cancer.  When injected inside the tumor, it is capable of creating and modulating an effective, slow and 
persistent antitumor immune response. Moreover, it is capable of improving the overall survival as well as 
the quality of life and general well being of the cancer patients. 
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Introduction
Naoum and colleagues published an interesting histological and 
immunohistochemical study on silicone fluid being used for soft 
tissue augmentation.[1] The authors reported that at a viscosity 
of 350 centistokes and at a temperature of 25°C, such a fluid 
was capable of soliciting mesenchymal and immunocompetent 
cell responses.[1] The study involved the injection of very low 
doses (0.05–0.07 ml) of silicone, followed by serial punch 
biopsies after 2 and 13 days, and 1, 2, 3, 4, and 12 months. 
Both a short-term perivascular lymphocytic infiltration as well 
as a delayed hypersensitivity reaction were found to be present. 
Subsequently, IgG–IgA deposits were detected around the 
vessel walls and were associated with a significant fibroblastic 
reaction.
The chemotactic properties of polydimethylsiloxane (silicone 
oil) on lymphocytes, monocytes, and macrophages and 
its viscosity that allows the trapping of some molecules in 
between the silicone chains, thereby releasing them at a very 
slow rate, might, in our opinion, be an ideal adjuvant of the 
local administration of cytokine in cancer treatment. This is 
especially true for head and neck cancers, where it is necessary 
to counteract the tumor expansion, which, otherwise, could 
lead to the impairment of vital functions. Moreover, this is 
equally important in certain organs or anatomical regions (such 
as the pancreas, liver or abdominal wall), where primary and/
or secondary nonresectable cancers might be infiltrated with 
such a compound to limit their growth and metastasis.
Recently, De Stefani and colleagues reported a long-term follow 
up of 201 patients affected by resectable ORL cancer.[2] The 
patients were treated with perilymphatic IL-2 injection (5000 
U) ten days before surgery, five days after surgery, and monthly 
thereafter for one year. The authors reported that the treated 
patients had a longer disease-free survival time, and a better 
overall survival as compared to the untreated patients. Further, 
other studies have reported positive results in patients whose 
tumor mass was injected with IL-2.[3–4]
Materials and Methods
Informed consent and selection criteria
Our study was conducted between January 2004 and December 
2006. It involved 15 patients (six males, and nine females) aged 
between 28 and 78 years [Table 1]. The study was approved 
by the human ethics committee at the University of Modena 
and Reggio Emilia, and conforms to the provisions of the 
Declaration of Helsinki in 1995 (as revised in Edinburgh 2000). 
The study was clearly explained to the patients, and a signed 
informed consent was obtained stating that the patients agreed 
to voluntarily participate in the study and that they were free to 
withdraw from the study whenever they decide to do so. The 
patient selection criteria included the following:
1.  Patients who have locally advanced and quickly growing 
cancer that is life threatening.
2.  Patients who have already completed all the prescribed 
chemoradiation protocols and were already discharged 
from the cancer centre before joining the study.
Procedure
The patients were injected once a week for one month with 
0.25 ml of polydimethylsiloxane medical grade (viscosity 
350 centistokes at 30°C; Eurosilicone, APT, France). 
Polydimethylsiloxane was mixed with 300.000 units of 
lyophilized human recombinant IL-2 (Proleukin-Chiron) by 
strong and prolonged shaking at 37°C for 5 min. We chose IL-2 
because of its reported safe and effective use at low doses in 
humans. The injection was performed under local anesthesia (1 
ml 1% carbocaine + 1:100.000 Epinephrine injected with 21 
Table 1: Characteristics of the patients enrolled in the study
Number   Pati  ent initi  als  Age  Sex  Diagnosis
of pati  ents (N).
1  C.K.  28  F  Ethmoid cancer with skull and meningeal inﬁ  ltration
2  F.O.  68  M  Anaplastic thyroid cancer
3  G.G.  42  M  Cancer of pyriform sinus with neck invasion
4  Z.N.  74  M  Left maxillary sinus cancer, with orbit and nasal fossa inﬁ  ltration. Pain. and 
        ocular globe extrusion by the tumor mass
5  S.G.  72  M  Parotid cancer with multiple neck metastasis
6  A.A.  62  F  Thyroid metastatic follicular cancer with a big local recurrence
7  B.M.  65  F  Cancer of the tongue
8  Z.G.  58  M  Cancer of parotid gland. Local relapse
9  P.C.  51  M  Cancer of the larynx with left neck involvement
10  F.R.  56  F  Pancreatic cancer with peritoneal involvement
11  U.T.  52  F  Metastatic left neck mass from previous breast cancer
12 M.M.H.  57  F  Pancreatic  cancer
13  P.T.  78  F  Bowel cancer with peritoneal involvement 
14  B.M.  45  F  Ovarian cancer with peritoneal involvement
15  F.L.  40  F  Ovarian cancer with massive pelvic invasion3 3
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G needle), and the anesthetic was injected along the silicone-
injecting needle track. Twenty minutes later, we approached the 
tumor mass with an 18 G needle connected with a Luer Lock 
glass syringe that contained polydimethylsiloxane-dispersed 
cytokine. The needle was fixed for at least 0.5 cm into the 
cancer bulk, and this was guided by ultrasound in order to 
avoid the injury of any blood vessels. When the tip of the 
needle was correctly placed into the tumor, the plunger was 
slightly withdrawn in order to confirm that we did not hit any 
blood vessel that was not visible with the ultrasound. This was 
followed by a slow and firm injection of the syringe content. The 
procedure was repeated in different areas of the tumor every 
week for one month. Symptoms and vital signs were recorded 
during the follow-up visits. 
Histopathology
Biopsies were taken from the tumor mass before the study 
was started and one week after the fourth injection. They 
were processed into paraffin blocks, and 4 µm sections were 
taken and examined by two independent pathologists for 
determining the percentage of the tumor containing a significant 
inflammatory reaction using an image analysis system (IAS). 
The occurrence of such a reaction was confirmed if bands of 
lymphocytes were present in the vicinity of the tumor and some 
of them infiltrated the actual tumor mass. This also included the 
presence of areas of dense fibrosis in the vicinity and within the 
tumor.[5] Data obtained by the independent pathologists were 
then added up, and the average percentage was calculated. 
The inter-observer variability was very low (<0.03%) and 
estimation of the 95% confidence limits required a maximum 
of 15 randomly selected high-power fields (magnification: 
x400) to be analysed by each pathologist. The IAS consisted of 
an observer-interactive computerized image analysis (SAMBA 
microscopic image processor; Meylan, France), whose hardware 
and software have been described by Brugal and colleagues.[6] 
This system is fitted with a standard Axioplan microscope with 
an automated stage (Carl Zeiss; Oberkochen, Germany) that 
allows a precise location of a particular field through XYZ 
axis plotting, a color video camera (Sony Corporation; Tokyo, 
Japan), an image analysis processor (Matrox; Montreal, QC, 
Canada), and a personal computer (Pentium 2, 166-MHZ 
processor; Intel; Santa Clara, CA). 
CT scan imaging
CT scans of the tumors were performed one week after the 
study was over and were compared with the ones performed 
at the beginning of the study. CT scans were obtained and 
re-digitized using anatomy modeling software (Anatomy 
Modelling, Theraplan Plus). The tumors were evaluated and 
outlined on each image slice that contained a mass by consensus 
reached by two independent radiologists, both of whom were 
blinded to the study. The tumor volume was then calculated 
using a summation of areas technique  with radiotherapy 
planning software (Theraplan Plus, version 3.18), taking into 
account the CT slice thickness.[7–10]
Assessing the quality of life and general wellbeing of 
the patients
The quality of life and general wellbeing of the patients were 
objectively assessed at the beginning of the study and one week 
after the study was over by using the following standardized 
and validated Karnofsky performance scores:[11]
●  100% – normal, no complaints, no signs of disease. 
●  90% – capable of normal activity, few symptoms or signs 
of disease. 
●  80% – normal activity with some difficulty, some symptoms 
or signs. 
●  70% – caring for self, not capable of normal activity or 
work. 
●  60% – requiring some help, can take care of most personal 
requirements. 
●  50% – requires help often, requires frequent medical 
care. 
●  40% – disabled, requires special care and help. 
●  30% – severely disabled, hospital admission indicated but 
no risk of death. 
●  20% – very ill, urgently requiring admission, requires 
supportive measures or treatment. 
●  10% – moribund, rapidly progressive fatal disease 
processes. 
●  0% – death.
Statistical analysis
Statistical analysis was performed on the data obtained from 
the 15 patients using a statistical software package (SAS; SAS 
Institute; Cary, NC). The two-tailed student’s t test was used 
to determine any significant difference between the Karnofsky 
scores before and after the treatment, between the size of the 
tumor on CT scan before and after the treatment, and between 
the percentage of tumor inflammatory reaction before and after 
the treatment. Results were calculated as mean ± SD, and a 
p-value < 0.05 was considered significant. The correlation 
coefficient (r2) was calculated using the Spearman method 
in order to determine any significant association between 
the reduction in tumor size and the tumor inflammatory 
reaction. 
Results
The procedure was reported to be well tolerated by the patients, 
and the major side effects observed were fever (38–40°C) 
and mild to moderate pain, which were alleviated by the 
administration of tramadol and ketoprophen  [Table 2]. In 
one patient with thyroid anaplastic cancer and cervical spine 4 4
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Table 2: Comparison of the changes taking place in the patients and their tumors before and after 
treatment
N  Percentage   Percentage  Percentage  Side eﬀ  ects  Prognosis  Survival  Performance  Performance  Cause
  decrease   of tumor  of tumor  accompanying  before  aft  er  Status  Status  of
  in tumor size   immune  immune  treatment  the  treatment  (Karnofsky  (Karnofsky  death
 following   reacti  on  reacti  on    treatment  (months)  score)  score)
  treatment, as   before  aft  er    started    before  aft  er
  determined by  treatment, as   treatment, as    (months)    treatment  treatment
  CT scan (mm2) determined    determined
    by IAS   by IAS
   (￿m2)  (￿m2) 
1  38 0 46  Chills,  and  1  9  30  100  Cerebro-
      short-term            meningeal
      fever          cancer
2  30 0 42  Neck  pain  3  12  70  100  Metastasis  to 
        requiring opiods           cervical spine
        in the last           and lungs
      injection  cycle; 
      short-term  fever. 
3  35 2 40  Short-term  fever;    1  4  80  100  Sepsis
        pain at the end 
      of  injection  cycle 
      alleviated  by 
      administration  of 
      tramadol  and 
      ketoprophen
4  29 7 35  Fever  and  chills;  3  8  30  80  Hemorrhage 
        facial pain at the 
      end  of  the 
      injection  cycle.
5  20  0  30  Mild fever, and late   1  6  30  60  Lung metastasis
      onset  of  moderate 
      pain  alleviated 
      by  administration 
      of  tramadol
6  12 4 27  Mild  fever  3  9  60  90  Acute 
               pulmonary 
               insufﬁ  ciency 
               due  to  lung 
               metastasis
7  0 (but, no  2  10  Mild fever  3  Still alive  60  100 
  increase in size)
8  10  1  17  Mild fever, and late   6  16  60  90  Liver metastasis,
        onset of moderate           ascites, and
        pain alleviated by           pulmonary
      administration  of            complications
      tramadol
9  70 1 81  Mild  fever  3  Still  alive  20  100
10  39 2 50  none  1  2  20  20  Cachexia,  and 
               heart  failure
11  25 2 36  none  1  6  20  60  Hearth–lung 
               insufﬁ  ciency
12  0 (but, no  0  11  none  3  6  40  80  Liver 
  increase in size)                 insufﬁ  ciency
13  0 (but, no  0  14  none  1  2  20  20  Cardiovascular 
  increase in size)                 insufﬁ  ciency
14  22 1 38  Mild  fever  6  Still  alive  60  90
15  39 1 44  Mild  fever  1  8  20  60  Renal 
               metastasis
The mean reduction in tumor size was 0% at the beginning of the study, as compared to 24.6% – 18.9 SD one week after the study was over (p < 0.0001). The 
mean percentage of the tumor displaying a severe immune reaction was 1.53 – 1.88 SD at the beginning of the study, while it was 34.73 – 18.28 SD one week 
after the study was over (p < 0.0001). The mean value of Karnofsky score was 41.3 – 21.3 SD at the beginning of the study, while it was 76.7 – 27.4 SD one week 
after the study was over (p = 0.0005). 5 5
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Figure 1: A and B. Laryngeal cancer lesion with neck involvement 
at the beginning of the study and after chemoradiation therapy. C, 
D and E. Intratumor injections (once per week for one month) of 
the same lesion with silicone oil mixed with IL-2 and progressive 
destruction of the lesion. F. The appearance of the lesion one 
week after the study was over
infiltration, a significant increase in neck pain was observed 
during treatment, and this was relieved using morphine (30 
mg/daily). 
Comparison of the Karnofsky scores revealed that the quality of 
life and general well being of the patients improved significantly 
at the end of study [Table 2]. The mean value of such score was 
41.3 ± 21.3 SD at the beginning of the study, while it was 76.7 
± 27.4 SD at its end; p = 0.0005. This was associated with 
improved survival, whereby the prognosis of the patients before 
the beginning of the study ranged between 1 and 6 months, 
while their overall survival after treatment was between 2 and 
12 months with three patients still remaining alive [Table 2, 
Figure 1]. 
Comparison of the CT scans of the patients’ tumor at the 
beginning of the study and at its end revealed that a significant 
decrease in tumor size was observed in 12 patients [Table 2]. 
Such a reduction reached 70% in one patient. In the remaining 
three patients, although there was no reduction in the tumor 
size, such tumors stopped growing completely. Accordingly, 
the mean reduction in tumor size observed in our study was 
0% at the beginning of the study as compared to 24.6% ± 18.9 
SD one week after the study was over; p < 0.0001. 
The abovementioned CT scan results were further confirmed 
by the results obtained from the histopathological analysis of the 
multiple biopsies taken from the tumor at the beginning of the 
study and one week after its end using an IAS. Examination of 
the tumor site following treatment revealed a rapid or delayed 
accumulation of fluid inside the tumor, which was associated 
with an intense inflammatory fibrotic reaction enveloping and 
penetrating the tumor mass. The results obtained by the two 
independent pathologists who performed the analysis revealed 
that the mean percentage of the tumor displaying a severe 
immune reaction was 1.53 ± 1.88 SD at the beginning of the 
study, while the mean percentage was 34.73 ± 18.28 SD one 
week after the study was over; p < 0.0001 [Table 2]. In the 
three patients whose tumor did not decrease in size, but had 
also stopped growing completely, the pathologists observed 
the presence of a dense rim of fibrotic tissue encircling the 
tumor. A significant correlation (r2 = 0.968; p < 0.0001) was 
found between the percentage reduction in tumor size and the 
percentage of tumor immune reaction one week after the study 
was over [Figure 2].
Discussion
There are several risks associated with the continuous growth 
of the cancer mass, such as compression and infiltration of 
vital structures, which often result in functional impairment in 
the patients. Our results showed that multiple injections with 
silicone oil that was mixed with IL-2 in different regions of the 
tumor resulted in a significant reduction in the tumor size in 
most of the cases, while it resulted in confining the tumor in 
others. This was achieved by acute and chronic recruitment of 
lymphocytes and monocytes to the tumor, thereby resulting 
in inflammation, edema, and fibrosis of the injected areas and 
Figure 2: Correlation between percentage reduction in tumor size 
and percentage of the tumor showing a severe immune reaction, 
as determined by CT scan and image analysis, respectively. Both 
parameters were determined one week after the study was over 
(r2 = 0.968, p < 0.0001)6 6
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their surroundings. This ability of the silicone oil to cause both 
acute and chronic recruitment of lymphocytes and monocytes 
could be explained by its ability to slowly release IL-2 due to the 
hydrophobic surface of silicone that will cause the denaturing 
of proteins absorbed into it. In our study, in addition to be 
able to successfully recruit monocytes to the injections sites, 
such monocytes were also able to react to the silicone oil by 
increasing their cytokine production.
The hypothesis to mix medical-grade silicone oil with cytokines 
in order to induce both chemotaxis and slow cytokine release, 
thereby improving the biologic effect of the cytokine is quite 
intriguing. Some experimental studies have investigated the 
effect of silicone itself or silicone mixed with complete or 
incomplete Freund’s adjuvant.[12–15] Naim and colleagues 
investigated the induction of hypergammaglobulinemia and 
macrophage activation by silicone oil in female ASW mice, 
showing that intraperitoneal injection of 0.5 ml of this oil 
resulted in an increase in the total serum IgM and IgG.[16] 
Furthermore, the peritoneal macrophages of these mice 
produced higher levels of IL-1-β, IL-6, and tumor necrosis 
factor alpha (TNF-α) as compared with the control. Similar 
findings were reported in another study where human 
monocytes were challenged in vitro with silicone oil as 
compared with the tissue culture polystyrene.[17] On the other 
hand, Chang and co-workers reported that injecting Lewis 
rat model intraperitoneally with silicone in conjunction with 
heat-killed Mycobacterium tuberculosis and tumor cells (EL4) 
failed to enhance the immune response directed against the EL4 
cells in the peritoneal cavity.[13] Picha and Goldstein evaluated 
both the adjuvant and antigenic properties of low molecular 
weight silicone and fumed silica, which were variously mixed   
with complete and incomplete Freund’s adjuvant.[14] In this 
experimental model that was followed up for 120 days, the 
silicone oil was not an effective adjuvant and the fumed silica 
was not an effective antigen. Nevertheless, a delayed immune 
reaction was observed. 
In our study, we used low dosages of highly pure medical-grade 
silicone oil that was moderately viscous so that it does not engulf   
the immunocompetent cells. The silicone used had a glucose-
linked polydimethylpolysiloxane polymer chain. It has been 
argued that polydimethylsiloxane could be capable of producing 
an immune response in guinea pigs, as demonstrated by the 
macrophage-inhibiting technique.[18] Heggers and colleagues 
hypothesized that macrophages may convert silicone to silica 
by means of NADP-dependent pathway, which results in the 
production of superoxide radicals.[19] The latter may attack the 
silicone methyl bond of siloxane, thus releasing silica inorganic 
ion. Smith and colleagues detected silicone molecules in the 
Golgi apparatus, rough endoplasmic reticulum and at both 
ends of the lymphocyte–macrophage bridges.[18] These findings 
support the hypothesis about the intracellular involvement of 
this compound as well as about its interactive role between 
lymphocytes and macrophages. Wedler, and Lavey and Pearl 
attempted to characterize this silicone–protein interaction, 
suggesting the hypothesis of an induction hapten-like molecular 
complex.[20,21]
From the experimental results and hypotheses reported earlier, 
it seems that there could be a good rationale behind endorsing 
the usage of silicone oil as a locally injected cytokine amplifier 
within the tumor. According to this and on the basis of the results 
obtained in this study, one could argue that a better exposure of 
the cytokine molecules on the silicone oil framework, as well 
as their slow bioavailability in the tumor microenvironment 
might enhance the immunological response against the tumor. 
Moreover, silicone itself might allow to effectively expose the 
tumor antigens so that the latter could become better targets 
for the killer lymphocytes and macrophages. Silicone oil is 
also capable of eliciting a humoral-type immune response, 
as demonstrated by the increase in the blood titers of certain 
immunoglobulins.
TNF-α is a cytokine often released by macrophages during 
the chemotactic response, and it has a strong antitumor effect. 
Accordingly, we will be mixing this cytokine with silicone oil 
and injecting the mixture into different tumor areas in further 
studies that will be conducted at our laboratory. Rathjen and 
Aston recently patented designing ligands that could bind 
to human TNF-α resulting in modifications of its biological 
activity.[22] Such modifications included inhibition of the TNF-
α-induced endothelial procoagulant activity, enhancement of 
fibrin deposition inside the tumor and enhancement of the 
cytotoxicity and the receptor binding activity of the TNF-α 
on the tumor cells.[22] Similarly, Kettling and co-workers 
recently patented their study that focused on specific proteases, 
fragments, and derivatives that could affect the TNF-α binding 
ability.[23]
Conclusion
Our study demonstrated the effectiveness of the use of silicone 
oil as a slow cytokine-release adjuvant in reducing tumor size, 
confining local tumor growth and improving survival and general 
wellbeing of the cancer patients. This technique, according to 
our protocol, is relatively painless and safe. It is capable of 
significantly eliciting a rapid and delayed swelling engulfing 
and penetrating the tumor, caused by heavy lymphocytic and 
monocytic infiltration of the tumor as well as by intra and extra 
tumor edema and fibrosis. Further laboratory investigations 
are urgently required for the enhanced definition of the 
mechanism(s) of action of the injected mixture in our study 
and to potentially use such mechanism(s) for inducing effective 7 7
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tumor regression. In addition to expanding on the current 
study with IL-2, we propose that other biological compounds 
such as TNF-α could be dispersed in polydimethylsiloxane as 
a single drug or as a sequential multidrug schedule for local 
tumor immunotherapy.
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